Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.

Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen PM.

Oncologist. 2007 Mar;12(3):312-9.

3.

[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C.

Dtsch Med Wochenschr. 2002 Jan 18;127(3):78-82. German.

PMID:
11797144
4.

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.

Anticancer Drugs. 2009 Jun;20(5):396-402. doi: 10.1097/CAD.0b013e32832a2dc1.

PMID:
19287306
5.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A.

J Clin Oncol. 2006 Jan 20;24(3):394-400.

PMID:
16421419
6.

Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer.

Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, Saggio G, Biondi E, Massa E, Mantovani G.

Anticancer Res. 2004 May-Jun;24(3b):1935-40.

7.

A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.

Xiong JP, Zhang L, Zhong LX, Qiu F, Xu J, Tao QS, Xiang XJ, Yu F, Tang XM.

Anticancer Drugs. 2007 Oct;18(9):1103-7.

PMID:
17704661
8.

Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G.

Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11. Epub 2007 Apr 12.

PMID:
17429632
9.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie.

J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378.

PMID:
18349393
10.

Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.

Del Freo A, Fiorentini G, Sanguinetti F, Muttini MP, Pennucci C, Mambrini A, Pacetti P, Della Seta R, Lombardi M, Torri T, Cantore M.

In Vivo. 2006 Nov-Dec;20(6A):743-6.

11.

A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.

Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ.

Chemotherapy. 2008;54(3):228-35. doi: 10.1159/000140467. Epub 2008 Jun 18.

PMID:
18560231
12.

Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.

Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.

Cancer Chemother Pharmacol. 2009 Feb;63(3):433-9. doi: 10.1007/s00280-008-0753-3. Epub 2008 Apr 9.

PMID:
18398608
13.

[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].

Muto O, Ando H, Ono T, Itagaki H, Kobayashi Y, Onuki M, Akashi T, Tanaka Y, Hanaoka T.

Gan To Kagaku Ryoho. 2007 Apr;34(4):579-81. Japanese.

PMID:
17431344
14.

The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.

Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.

Gan To Kagaku Ryoho. 2009 May;36(5):797-801.

PMID:
19461180
15.

Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.

Fuse N, Doi T, Ohtsu A, Takeuchi S, Kojima T, Taku K, Tahara M, Muto M, Asaka M, Yoshida S.

Jpn J Clin Oncol. 2007 Jun;37(6):434-9.

PMID:
17656481
17.

Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.

Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC.

Chemotherapy. 2009;55(4):200-6. doi: 10.1159/000219434. Epub 2009 May 19.

PMID:
19451710
18.

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.

Jpn J Clin Oncol. 2007 Sep;37(9):686-91. Epub 2007 Aug 24.

PMID:
17720736
19.

[A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer].

Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T.

Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. Japanese.

PMID:
17301527
20.

Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.

Lorenz M, Staib-Sebler E, Gog C, Proschek D, Jauch KW, Ridwelski K, Hohenberger W, Gassel HJ, Lehmann U, Vestweber KH, Padberg W, Zamzow K, Müller HH.

Zentralbl Chir. 2003 Feb;128(2):87-94.

PMID:
12632273

Supplemental Content

Support Center